The extended transition period for new EU regulations on medical devices is giving stakeholders more time on a workload that was “probably underestimated”. The sector has a large industrial presence in Ireland.
Multibillion firms Abbott Technologies and Edward Lifesciences have been slugging it out in a patent battle over a device for fixing leaky heart valves. The High Court has now entered the fray, dismissing claims of an abuse of process.
Abbott Laboratories (market cap: €142 billion) has been battling Edwards Lifesciences (market cap: €42 billion) in US and UK courts over the Pascal, Edwards' device for fixing leaky heart valves. Now the fight is coming to Ireland.
© 2023 Currency Media Limited
